Tarsus Pharmaceuticals, Inc.TARSNASDAQ

Revenue (LTM)

$451M

+146.7% YoY

Net Income (LTM)

$-66M

+42.5% YoY

Free Cash Flow

$-22M

Revenue CAGR (5Y)

+67.7%

Marginsdeclining

FCF($0.0B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	57	26↓54.7%	17↓32.4%	183↑948.6%	451↑146.7%
Gross Profit	55	25↓54.8%	16↓36.2%	170↑973.1%	421↑147.3%
Operating Income	-12	-63↓415.9%	-143↓128.3%	-121↑15.8%	-71↑41.1%
Net Income	-14	-62↓349.1%	-136↓118.9%	-116↑15.0%	-66↑42.5%
EBITDA	-13	-60↓343.6%	-132↓120.5%	-106↑19.1%	-54↑49.7%
EPS Diluted	-0.67	-2.52↓276.1%	-4.62↓83.3%	-3.07↑33.5%	-1.59↑48.2%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	171	72↓58.2%	225↑213.9%	95↓57.8%	184↑93.7%
Total Current Assets	176	225↑28.1%	256↑13.6%	357↑39.3%	523↑46.6%
Total Assets	179	228↑27.4%	265↑16.5%	377↑42.0%	562↑49.1%
Total Current Liabilities	11	15↑34.4%	37↑139.4%	81↑118.2%	136↑68.3%
Total Liabilities	12	35↑187.1%	69↑95.9%	152↑122.6%	219↑43.5%
Total Equity	167	193↑15.7%	197↑2.1%	225↑14.0%	343↑53.0%
Total Debt	2	20↑968.6%	30↑49.5%	72↑139.8%	94↑29.2%
Net Debt	-169	-51↑69.6%	-195↓278.5%	-22↑88.5%	-90↓302.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	4	-49↓1408.2%	-117↓139.6%	-83↑29.3%	-12↑85.0%
Capital Expenditure	-1	-1↑13.7%	-6↓987.4%	-2↑71.5%	-10↓529.2%
Free Cash Flow	3	-50↓1666.6%	-123↓148.3%	-85↑31.2%	-22↑73.6%
Stock-Based Comp	8	13↑59.2%	20↑47.3%	28↑40.3%	42↑50.0%
Net Change in Cash	3	-100↓3231.4%	153↑253.8%	-128↓183.2%	89↑169.6%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance